Friday, June 3

Session Title: Pediatric Oncology I  
Session Type: Oral Abstract Session  
Date: Fri, June 3  
Location: S504  
Time: 3:00 PM - 6:00 PM  
Speaker Name: Veronique Minard-Colin

- **5:12 PM - 5:24 PM**  
Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. (Abstract #10507)

Saturday, June 4

Session Title: The View Beyond Single-Agent Checkpoint Blockade  
Session Type: Clinical Science Symposium  
Date: Sat, June 4  
Location: Hall D1  
Time: 8:00 AM - 9:30 AM  
Speaker Name: Jeffrey R. Infante, MD

- **8:24 AM - 8:36 AM**  
A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors. (Abstract #101)
Session Title: Lung Cancer—Non-Small Cell Metastatic
Session Type: Poster Session
Date: Sat, June 4
Location: Hall A
Time: 8:00 AM - 11:30 AM
Speaker Name: David A. Smith, MD

- **Poster Board: #351**
  Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR). (Abstract #9028)

Session Title: Genitourinary (Prostate) Cancer
Session Type: Poster Session
Date: Sat, June 4
Location: Hall A
Time: 1:00 PM - 4:30 PM
Speaker Name: Johann S. De Bono, MD, MSc, PhD, FRCP, FMedSci, MB ChB

- **Poster Board: #274**
  Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study). (Abstract #5017)

Session Title: Melanoma/Skin Cancers
Session Type: Poster Session
Date: Sat, June 4
Location: Hall A
Time: 1:00 PM - 4:30 PM
Speaker Name: Grant A. McArthur, MD, PhD, FRACP, MBBS, MB, BS

- **Poster Board: #135**
  Efficacy of cobimetinib (C) and vemurafenib (V) in advanced BRAF-mutated melanoma patients (pts) with poor and favorable prognosis in the coBRIM phase III study. (Abstract #9530)

Session Title: Developmental Therapeutics—Immunotherapy
Session Type: Oral Abstract Session
Date: Sat, June 4
Location: Hall B1
Time: 1:15 PM - 4:15 PM
Speaker Name: Samuel Funt, MD
• **2:39 PM - 2:51 PM**
  Correlation of peripheral and intratumoral T-cell receptor (TCR) clonality with clinical outcomes in patients with metastatic urothelial cancer (mUC) treated with atezolizumab. (Abstract #3005)

---

**Session Title:** Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant  
**Session Type:** Oral Abstract Session  
**Date:** Sat, June 4  
**Location:** Arie Crown Theater  
**Time:** 3:00 PM - 6:00 PM  
**Speaker Name:** Tara L. Lin, MD

• **5:12 PM - 5:24 PM**
  Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥ 65 with acute myelogenous leukemia. (Abstract #7007)

---

**Sunday, June 5**

**Session Title:** Gastrointestinal (Colorectal) Cancer  
**Session Type:** Oral Abstract Session  
**Date:** Sun, June 5  
**Location:** Hall B1  
**Time:** 8:00 AM - 11:00 AM  
**Speaker Name:** Johanna C. Bendell, MD

• **8:24 AM - 8:36 AM**
  Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). (Abstract #3502)

---

**Session Title:** Genitourinary (Nonprostate) Cancer  
**Session Type:** Oral Abstract Session  
**Date:** Sun, June 5  
**Location:** Hall D2  
**Time:** 8:00 AM - 11:00 AM  
**Speaker Name:** Arjun Vasant Balar, MD

• **8:00 AM - 8:12 AM**
  Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.). (Abstract #LBA4500)
Session Title: Genitourinary (Nonprostate) Cancer
Session Type: Oral Abstract Session
Date: Sun, June 5
Location: Hall D2
Time: 8:00 AM - 11:00 AM
Speaker Name: Robert Dreicer, MD, MS

- 8:36 AM - 8:48 AM
  Updated efficacy and > 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (mUC). (Abstract #4515)

Session Title: Breast Cancer—HER2/ER
Session Type: Poster Session
Date: Sun, June 5
Location: Hall A
Time: 8:00 AM - 11:30 AM
Speaker Name: Maura N. Dickler, MD

- Poster Board: #8
  A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC). (Abstract #520)

Session Title: Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Session Type: Poster Session
Date: Sun, June 5
Location: Hall A
Time: 8:00 AM - 11:30 AM
Speaker Name: Sylvia Adams, MD; Suzette Delaloge, MD; Adam Brufsky, MD, PhD; David Miles, MD

- Poster Board: #114
  Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). (Abstract #1009)

- Poster Board: #118
  Overall survival of patients with HER2-negative metastatic breast cancer treated with a first-line paclitaxel with or without bevacizumab in real-life setting: Results of a multicenter national observational study. (Abstract #1013)

- Poster Board: #179
  Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study. (Abstract #1074)

- Poster Board: #203a
  COLET (NCT02322814): A multistage, phase 2 study evaluating the safety and efficacy of
cobimetinib (C) in combination with paclitaxel (P) as first-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC). (Abstract #TPS1100)

**Session Title:** Plenary Session Including the Science of Oncology Award and Lecture  
**Session Type:** Plenary Session  
**Date:** Sun, June 5  
**Location:** Hall B1  
**Time:** 1:00 PM - 4:00 PM  
**Chair and/or Co-Chairs:** Julie Vose, MD, MBA, FASCO, University of Nebraska Medical Center; Lynn Mara Schuchter, MD, University of Pennsylvania

---

### Monday, June 6

**Session Title:** Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant  
**Session Type:** Poster Session  
**Date:** Mon, June 6  
**Location:** Hall A  
**Time:** 8:00 AM - 11:30 AM  
**Speaker Name:** Daniel Aaron Pollyea, MD, MS

- **Poster Board: #1**  
  Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥ 65 years ineligible for standard induction therapy. (Abstract #7009)

---

**Session Title:** Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia  
**Session Type:** Poster Session  
**Date:** Mon, June 6  
**Location:** Hall A  
**Time:** 8:00 AM - 11:30 AM  
**Speaker Name:** Matthew Steven Davids, MD, MMSc; Andrew David Zelenetz, MD, PhD

- **Poster Board: #83**  
  Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL). (Abstract #7527)

- **Poster Board: #84**  
  Integrated safety analysis of venetoclax monotherapy in chronic lymphocytic leukemia (CLL). (Abstract #7528)

- **Poster Board: #122**  
  Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma. (Abstract #7566)
Session Title: Hematologic Malignancies—Plasma Cell Dyscrasia  
Session Type: Poster Session  
Date: Mon, June 6  
Location: Hall A  
Time: 8:00 AM - 11:30 AM  
Speaker Name: Shaji Kumar, MD

- **Poster Board: #297**  
  Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma. (Abstract #8032)

Session Title: Lung Cancer—Non-Small Cell Metastatic  
Session Type: Oral Abstract Session  
Date: Mon, June 6  
Location: Arie Crown Theater  
Time: 9:45 AM - 12:45 PM  
Speaker Name: Hiroshi Nokihara, MD, PhD

- **12:09 PM - 12:21 PM**  
  Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. (Abstract #9008)

Session Title: Breast Cancer—HER2/ER  
Session Type: Oral Abstract Session  
Date: Mon, Jun 6  
Location: Hall D1  
Time: 1:15 PM - 4:15 PM  
Speaker Name: Sara A. Hurvitz, MD; Ander Urruticoechea, MD

- **1:15 PM - 1:27 PM**  
  Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE). (Abstract #500)

- **2:27 PM - 2:39 PM**  
  PHEREXA: A phase III study of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting. (Abstract #504)